NCT07176390View on ClinicalTrials.gov

A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)

PHASE2RecruitingINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

October 8, 2025

Primary Completion Date

March 8, 2027

Study Completion Date

September 3, 2029

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

Tulisokibart

Subcutaneous (SC) administration

DRUG

Placebo

SC Injection

DRUG

Methotrexate

Background Therapy - SC injection or oral administration. Per protocol, parenteral administration is allowed.

Trial Locations (4)

16635

RECRUITING

altoona center for clinical research ( Site 1005), Duncansville

33016

RECRUITING

Sweet Hope Research Specialty, Inc ( Site 1015), Hialeah

48439

RECRUITING

AA Medical Research Center ( Site 1027), Grand Blanc

80528

RECRUITING

Tekton Research, LLC. ( Site 1008), Fort Collins

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT07176390 - A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) | Biotech Hunter | Biotech Hunter